ClinicalTrials.gg
CompletedNCT06754943Updated Sep 9, 2025

To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105

A Phase 1 interventional study of Treatment A_Period 1 and Treatment B_Period 2 in Healthy, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by JW Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0104 and C2402 and administration of JW0105 in healthy volunteers under fasting conditions.

Read the detailed description

Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers

Exclusion criteria

Exclusion Criteria:

  • Subjects does not meet the inclusion Criteria
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Other
    Group 1

    * Treatment A: Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 * Treatment B: Administration alone of 1 tablet of JW0105

    Drug: Treatment A_Period 1 · Drug: Treatment B_Period 2 · Drug: Treatment A_Period 3 · Drug: Treatment B_Period 4

  • Other
    Group 2

    * Treatment A: Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 * Treatment B: Administration alone of 1 tablet of JW0105

    Drug: Treatment B_Period 1 · Drug: Treatment A_Period 2 · Drug: Treatment B_Period 3 · Drug: Treatment A_Period 4

Interventions

  • DrugTreatment A_Period 1

    * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 * Wash-out period: 21 days * Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment B_Period 2

    * Administration alone of 1 tablet of JW0105 * Wash-out period: 21 days * Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment A_Period 3

    * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 * Wash-out period: 21 days * Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment B_Period 4

    * Administration alone of 1 tablet of JW0105 * Wash-out period: 21 days * Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment B_Period 1

    * Administration alone of 1 tablet of JW0105 * Wash-out period: 21 days * Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment A_Period 2

    * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 * Wash-out period: 21 days * Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment B_Period 3

    * Administration alone of 1 tablet of JW0105 * Wash-out period: 21 days * Administration: Treatment B is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

  • DrugTreatment A_Period 4

    * Co-administration of 1 tablet of JW0104 and 1 tablet of C2402 * Wash-out period: 21 days * Administration: Treatment A is administered orally with 150 mL of water under fasting conditions

    Also known as: NA (Not Applicable)

06

What researchers measure

Primary outcomes

  1. AUCt

    Plasma concentrations are measured using a validated LC-MS/MS.

    Time frame: Day 1 (0 hour) ~ Day 3 (72 hour) post-dose in period 1, period 2, period 3, and period 4

  2. Cmax

    Plasma concentrations are measured using a validated LC-MS/MS.

    Time frame: Day 1 (0 hour) ~ Day 3 (72 hour) post-dose in period 1, period 2, period 3, and period 4

07

Study locations

1 site
  • Metro Hospital
    Anyang-si, Gyeonni-do 14096, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Jan 1, 2025
StartActual
Jan 17, 2025
Primary completionActual
Mar 24, 2025
CompletionActual
Apr 22, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06754943
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Jan 17, 2025
Primary completion
Mar 24, 2025
Completion
Apr 22, 2025
Last update
Sep 9, 2025

Study contacts

Sung-Dae Kwon
principal investigator · Metro Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion